Timing for Olaparib Initiation After Definitive Treatment
Olaparib should be initiated within 8 weeks of completing the last dose of first-line platinum-based chemotherapy in patients with BRCA-mutated ovarian cancer, or within 12 weeks for patients receiving niraparib or when bevacizumab is part of the regimen.
Evidence-Based Timing Guidelines
The timing window for initiating olaparib maintenance therapy varies based on the specific clinical scenario and trial protocols that established efficacy:
For BRCA-Mutated Ovarian Cancer (First-Line Maintenance)
- SOLO1 trial protocol: Patients were randomized within 8 weeks of their last dose of chemotherapy 12
- This 8-week window is the most stringent and well-established timeframe for BRCA-mutated disease
- The FDA label for Lynparza (olaparib) reflects this SOLO1 protocol timing 22
For HRD-Positive Disease with Bevacizumab (PAOLA-1)
- PAOLA-1 trial protocol: Patients started olaparib after a minimum of 3 weeks and up to a maximum of 9 weeks following completion of their last dose of chemotherapy 2
- This applies when olaparib is combined with bevacizumab maintenance
- The slightly longer window accommodates the continuation of bevacizumab therapy
For Non-BRCA Mutated Disease (PRIMA)
- PRIMA trial protocol: Patients were randomized within 12 weeks of the first day of the last cycle of chemotherapy 11
- This 12-week window applies to niraparib but provides context for broader HRD-positive populations
Clinical Algorithm for Timing
Step 1: Confirm Response Status
- Patient must have achieved complete response (CR) or partial response (PR) to platinum-based chemotherapy
- No clinical evidence of disease progression
Step 2: Determine Mutation Status and Treatment Plan
- BRCA-mutated (germline or somatic): Target initiation within 8 weeks of last chemotherapy dose
- HRD-positive receiving bevacizumab: Initiate between 3-9 weeks after last chemotherapy dose
- HRD-positive without bevacizumab: Consider up to 12 weeks based on PRIMA data
Step 3: Prioritize Earlier Initiation
- Within the allowable window, earlier initiation is preferable to maximize maintenance benefit
- Delays beyond protocol-specified windows may compromise efficacy outcomes
Critical Caveats
Why Timing Matters
The maintenance therapy concept requires initiating treatment while patients are in remission and before microscopic disease progression occurs. The SOLO1 trial demonstrated remarkable 7-year overall survival benefit (67% vs 46.5% alive at 7 years) 3, but this benefit depends on appropriate timing of initiation.
Common Pitfalls to Avoid
Waiting too long for count recovery: While hematologic recovery is important, don't delay beyond the protocol window. Dose modifications are available if needed at initiation.
Delaying for confirmatory testing: Genetic testing should be expedited during chemotherapy completion, not after, to avoid missing the initiation window.
Confusion about "last dose": The clock starts from the last dose of chemotherapy, not from the date of response assessment imaging.
Safety Considerations
- The FDA label specifies that olaparib treatment continues for up to 2 years or until disease progression 2
- Patients who derive continued benefit may be treated beyond 2 years at physician discretion
- Bevacizumab (when used) continues for up to 15 months total, including the period given with chemotherapy 2
Real-World Application
In clinical practice, aim to have all prerequisite testing (BRCA/HRD status, response assessment imaging) completed by week 6 after last chemotherapy to allow initiation by week 8. This requires proactive planning during the final chemotherapy cycles, not reactive scheduling after completion.
The 8-week window for BRCA-mutated disease represents the highest quality evidence from SOLO1 14, which showed the most dramatic progression-free survival benefit (median not reached vs 13.8 months, HR 0.30) and should be the default target for this population.